Becton, Dickinson [BDX] vs Hologic [HOLX] Detailed Stock Comparison
Becton, Dickinson
NYSE
Loading...
Hologic
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Becton, Dickinson wins in 11 metrics, Hologic wins in 8 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Becton, Dickinson | Hologic | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 36.04 | 27.76 | Hologic |
| Price-to-Book Ratio | 2.11 | 3.07 | Becton, Dickinson |
| Debt-to-Equity Ratio | 76.34 | 52.09 | Hologic |
| PEG Ratio | 11.82 | 14.17 | Becton, Dickinson |
| EV/EBITDA | 12.20 | 12.43 | Becton, Dickinson |
| Profit Margin (TTM) | 7.18% | 13.79% | Hologic |
| Operating Margin (TTM) | 16.01% | 25.48% | Hologic |
| EBITDA Margin (TTM) | 16.01% | 25.48% | Hologic |
| Return on Equity | 5.89% | 11.38% | Hologic |
| Return on Assets (TTM) | 3.69% | 6.69% | Hologic |
| Free Cash Flow (TTM) | $3.07B | $1.15B | Becton, Dickinson |
| Dividend Yield | 1.80% | N/A | N/A |
| 1-Year Return | -17.97% | -18.63% | Becton, Dickinson |
| Price-to-Sales Ratio (TTM) | 2.55 | 3.68 | Becton, Dickinson |
| Enterprise Value | $68.00B | $15.52B | Becton, Dickinson |
| EV/Revenue Ratio | 3.26 | 3.84 | Becton, Dickinson |
| Gross Profit Margin (TTM) | 42.81% | 56.32% | Hologic |
| Revenue per Share (TTM) | $72 | $18 | Becton, Dickinson |
| Earnings per Share (Diluted) | $5.16 | $2.41 | Becton, Dickinson |
| Beta (Stock Volatility) | 0.22 | 0.49 | Becton, Dickinson |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Becton, Dickinson vs Hologic Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Becton, Dickinson | 3.10% | 9.71% | 10.81% | 15.21% | -15.70% | -14.57% |
| Hologic | 0.19% | 1.34% | 4.87% | 21.15% | 4.32% | -5.13% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Becton, Dickinson | -17.97% | -26.61% | -23.17% | 33.78% | 179.52% | 265.18% |
| Hologic | -18.63% | -6.75% | 1.87% | 60.33% | 361.11% | 493.89% |
Performance & Financial Health Analysis: Becton, Dickinson vs Hologic
| Metric | BDX | HOLX |
|---|---|---|
| Market Information | ||
| Market Cap | $53.31B | $14.88B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,491,688 | 1,830,700 |
| 90 Day Avg. Volume | 2,881,043 | 1,903,103 |
| Last Close | $193.50 | $68.06 |
| 52 Week Range | $163.33 - $251.99 | $51.90 - $84.67 |
| % from 52W High | -23.21% | -19.62% |
| All-Time High | $287.32 (Jul 24, 2023) | $87.88 (May 01, 2023) |
| % from All-Time High | -32.65% | -22.55% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.01% |
| Quarterly Earnings Growth | -0.43% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.14% |
| Operating Margin (TTM) | 0.16% | 0.25% |
| Return on Equity (TTM) | 0.06% | 0.11% |
| Debt to Equity (MRQ) | 76.34 | 52.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $88.07 | $21.79 |
| Cash per Share (MRQ) | $2.38 | $8.47 |
| Operating Cash Flow (TTM) | $3.30B | $1.07B |
| Levered Free Cash Flow (TTM) | $3.50B | $760.11M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.80% | N/A |
| Last 12-Month Dividend | $3.03 | N/A |
Valuation & Enterprise Metrics Analysis: Becton, Dickinson vs Hologic
| Metric | BDX | HOLX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 36.04 | 27.76 |
| Forward P/E | 11.82 | 14.17 |
| PEG Ratio | 11.82 | 14.17 |
| Price to Sales (TTM) | 2.55 | 3.68 |
| Price to Book (MRQ) | 2.11 | 3.07 |
| Market Capitalization | ||
| Market Capitalization | $53.31B | $14.88B |
| Enterprise Value | $68.00B | $15.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.26 | 3.84 |
| Enterprise to EBITDA | 12.20 | 12.43 |
| Risk & Other Metrics | ||
| Beta | 0.22 | 0.49 |
| Book Value per Share (MRQ) | $88.07 | $21.79 |
Financial Statements Comparison: Becton, Dickinson vs Hologic
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BDX | HOLX |
|---|---|---|
| Revenue/Sales | $5.27B | $1.01B |
| Cost of Goods Sold | $3.02B | $628.00M |
| Gross Profit | $2.26B | $377.30M |
| Research & Development | $302.00M | $61.50M |
| Operating Income (EBIT) | $637.00M | $37.90M |
| EBITDA | $1.21B | $121.70M |
| Pre-Tax Income | $363.00M | $-28.50M |
| Income Tax | $55.00M | $-11.10M |
| Net Income (Profit) | $308.00M | $-17.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BDX | HOLX |
|---|---|---|
| Cash & Equivalents | $667.00M | $1.43B |
| Total Current Assets | $8.67B | $3.21B |
| Total Current Liabilities | $7.69B | $989.70M |
| Long-Term Debt | $17.67B | $2.47B |
| Total Shareholders Equity | $25.24B | $4.62B |
| Retained Earnings | $16.15B | $3.03B |
| Property, Plant & Equipment | N/A | $939.80M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BDX | HOLX |
|---|---|---|
| Operating Cash Flow | $941.00M | $28.40M |
| Capital Expenditures | N/A | $-24.70M |
| Free Cash Flow | $35.00M | $129.20M |
| Debt Repayment | $-1.00M | $-10.20M |
| Common Stock Repurchase | $0 | $-200.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BDX | HOLX |
|---|---|---|
| Shares Short | 4.69M | 5.15M |
| Short Ratio | 1.49 | 2.16 |
| Short % of Float | 0.02% | 0.03% |
| Average Daily Volume (10 Day) | 2,491,688 | 1,830,700 |
| Average Daily Volume (90 Day) | 2,881,043 | 1,903,103 |
| Shares Outstanding | 289.10M | 231.73M |
| Float Shares | 285.93M | 220.31M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.93% | 1.04% |
Dividend Analysis & Yield Comparison: Becton, Dickinson vs Hologic
| Metric | BDX | HOLX |
|---|---|---|
| Last 12-Month Dividend | $3.03 | N/A |
| Last 12-Month Dividend Yield | 1.80% | N/A |
| 3-Year Avg Annual Dividend | $3.16 | N/A |
| 3-Year Avg Dividend Yield | 0.40% | N/A |
| 3-Year Total Dividends | $9.48 | N/A |
| Ex-Dividend Date | Mar 10, 2025 | N/A |